Clinical Report: Evaluating Ultrasound as a Predictor of Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Overview

Expand on the variability in studies, mentioning specific types of studies included.

Background

Breast cancer is a prevalent malignancy, and neoadjuvant chemotherapy plays a crucial role in reducing tumor size and improving surgical outcomes. Accurate predictors of pathological response are essential for personalizing treatment and minimizing unnecessary toxicity. The increasing use of ultrasound technology in this context highlights the need for a comprehensive evaluation of its predictive capabilities.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

• Ultrasound has been identified as a potential early predictor of pathological response to neoadjuvant chemotherapy in breast cancer.
• Variability in study results indicates the necessity for a thorough evaluation of ultrasound's predictive accuracy.
• The systematic review adhered to PRISMA guidelines, ensuring methodological rigor in the literature search and data extraction.
• Quality assessment of included studies was conducted using QUADAS-2, focusing on bias risk in various domains.
• Meta-analysis results indicated the need for further research to solidify ultrasound's role in predicting treatment outcomes.

Clinical Implications

Healthcare professionals should consider incorporating ultrasound as a complementary tool for assessing treatment response in breast cancer patients undergoing neoadjuvant chemotherapy. Further validation of ultrasound's predictive capabilities may enhance personalized treatment strategies and improve patient outcomes.

Conclusion

The systematic review underscores the potential of ultrasound as a predictor of pathological response to neoadjuvant chemotherapy in breast cancer, while also highlighting the need for further research to confirm its efficacy.

References

1. Author(s)/Org, Source, Year -- Title
2. The ASCO Post, 2013 -- Response-Guided Neoadjuvant Therapy for Breast Cancer: A Promising Model Warranting Additional Investigation
3. European Radiology, 2023 -- Is it possible for multi-modal radiomics utilizing pre-treatment ultrasound and tomosynthesis to forecast the effectiveness of neoadjuvant systemic therapy in breast cancer?
4. The ASCO Post, 2025 -- Reevaluating Pathologic Complete Response as a Surrogate for Survival in Rectal Cancer
5. European Radiology, 2025 -- Assessment of Primary Tumour Changes on Breast MRI as an Indicator of Axillary Pathological Response in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
6. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025) - PMC
7. SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (UPDATE 2025) - PMC
8. Ultrasound for predicting pathological response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis - PMC
9. Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial | npj Breast Cancer